Cell Design Labs company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

celldesignlabs.com

Stage

Acquired | Acquired

Total Raised

$34.5M

Valuation

$0000 

About Cell Design Labs

Cell Design Labs is a biotherapeutics company that discovers and develops cell-based therapies. Using its proprietary technology platform for custom cell engineering, Cell Design Labs has been developing a portfolio of anticancer therapies. Initially focused on cancer, including both hematologic and solid tumors, this broad technology may also have applications in other complex diseases, such as autoimmune and degenerative disorders.

Cell Design Labs Headquarter Location

5858 Horton St Suite 240

Emeryville, California, 94608,

United States

510-398-1611

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cell Design Labs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cell Design Labs is included in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cell Design Labs Patents

Cell Design Labs has filed 5 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/18/2018

5/10/2022

Transcription factors, Small nuclear RNA, Clusters of differentiation, Molecular biology, Immunology

Grant

Application Date

6/18/2018

Grant Date

5/10/2022

Title

Related Topics

Transcription factors, Small nuclear RNA, Clusters of differentiation, Molecular biology, Immunology

Status

Grant

Latest Cell Design Labs News

Gilead Sciences to acquire Cell Design Labs in $567m deal

Jan 2, 2018

Gilead Sciences to acquire Cell Design Labs in $567m deal Gilead Sciences and its cell therapy subsidiary Kite have agreed to acquire Cell Design Labs, a biotherapeutics company that discovers and develops cell-based therapies, for about $567m. Based in Emeryville, California, Cell Design Labs is a pre-clinical stage company, focused on developing disruptive CAR-T and T cell receptor (TCR) therapies to advance discovery and development of new anti-cancer drugs. The transaction is expected to consolidate Gilead's recent $11.9bn acquisition of Kite Pharma. It also has the potential to help Gilead and Kite to speed up the development of next generation cellular therapy candidates. Gilead Sciences president and CEO John Milligan said: “This acquisition demonstrates our deep commitment to continuing to invest in future innovation in the field of cellular therapy, both internally and externally. “Cell Design Labs’ talented team of cell biology experts will augment and accelerate our work to bring forward new generations of CAR T and TCR therapies, building on our acquisition of Kite earlier this year and our efforts to improve care for people with advanced cancers.” Cell Design Labs is developing two technology platforms, synNotch and Throttle. synNotch is a synthetic gene expression system that responds to external cues which can be deployed to engineer chimeric antigen receptor T (CAR T) cells that need dual antigen recognition for activation. Throttle, on the other hand, is an on switch that modulates CAR T activity using small molecules. Cell Design Labs is also developing various pre-clinical product candidates that include therapies for prostate cancer and hepatocellular carcinoma that use the synNotch technology. Its lead pre-clinical candidate targets multiple myeloma. Cell Design Labs president and CEO Brian Atwood said: “Bringing our robust technology platforms under the Gilead umbrella, with its outstanding research and development capabilities and commitment to innovation, provides an exciting path forward for the development of the next generation of living therapies for patients with cancer.” As per the agreement terms, Gilead will buy all of the shares of Cell Design Labs, including a stake of nearly 12.2% of the latter held by Kite. Gilead will pay an initial upfront payment of around $175m, subject to certain adjustments. Cell Design Labs will also be entitled to receive $322m of additional payments that will be paid to all its shareholders with the exception of Kite. This amount will be based on the occurrence of certain events such as the achievement of development and approval milestones. The transaction, which will be subject to customary closing conditions, is anticipated to be completed shortly. Image: Gilead Sciences to buy Emeryville-based Cell Design Labs. Photo: courtesy of Stuart Miles at FreeDigitalPhotos.net. Share: Latest News

  • Where is Cell Design Labs's headquarters?

    Cell Design Labs's headquarters is located at 5858 Horton St, Emeryville.

  • What is Cell Design Labs's latest funding round?

    Cell Design Labs's latest funding round is Acquired.

  • How much did Cell Design Labs raise?

    Cell Design Labs raised a total of $34.5M.

  • Who are the investors of Cell Design Labs?

    Investors of Cell Design Labs include Gilead Sciences, Osage University Partners, Mission Bay Capital, Kite Pharma and Kleiner Perkins Caufield & Byers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.